How will biomarker-led diagnostics reshape respiratory medicine?

October 11, 2026
Asthma & COPD, COPD, Chronic Diseases, Diagnostics, biomarkers, clinical trial

By Dr Louise Ryan Murphy, Chronic obstructive pulmonary disease (COPD) is typically diagnosed and assessed through symptoms, lung function and …

Five Facts about COPD

October 11, 2026
Medical Communications Asthma & COPD, COPD, Five Facts, HRT, Smoking Cessation, chronic bronchitis, emphysema, smoking

1 Chronic obstructive pulmonary disease is a group of progressive lung conditions, principally emphysema and chronic bronchitis, that restrict airflow …

Agentic commercial: how AI creates dialogue with HCPs and patients to help medicines reach them faster

October 11, 2026
Licenses/Quality Standards, Marketing, Sales & Marketing Training AI, Devices, Diagnostics, Hospital Management, Pharmacy, biopharma, medical adoption, pharmaceutical

By Chris Moore Commercial engagement in biopharma used to centre largely on direct conversations between sales reps and physicians or …

Fortysomethings’ non-attendance at NHS Health Checks raises concerns, says study

October 11, 2026
Chronic Diseases, NHS, Oncology, cardiovascular disease, survey

People in their forties account for almost three-quarters of those who do not attend NHS Health Checks, highlighting the challenge …

NICE recommends daratumumab quadruplet for newly diagnosed multiple myeloma

October 8, 2026
NICE, Oncology, drug recommendation, drug regulation

NICE has published final draft guidance recommending daratumumab with bortezomib, lenalidomide and dexamethasone (D-VRd) for previously untreated adults with multiple …

AstraZeneca’s Trixeo approved in EU for asthma

October 8, 2026
Asthma & COPD, AstraZeneca, EU

AstraZeneca’s Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate) has been approved in the European Union as a maintenance treatment for asthma in …

Amplio reports early human data for novel methotrexate approach in rheumatoid arthritis

October 7, 2026
Rheumatology, clinical testing, immunology, rheumatoid arthritis

Amplio Pharma has reported phase 1b results for NovoBioJect, an investigational combination of low-dose methotrexate (MTX) and novobiocin being developed …

Survodutide delivers up to 13.1% weight loss in phase 3 obesity and diabetes trial

October 6, 2026
Diabetes, GLP-1, Obesity, diabetes, obesity, phase 3 trial

Boehringer Ingelheim’s investigational survodutide produced weight loss of up to 13.1% after 76 weeks in people with obesity or overweight …

ESTEVE CDMO adds $17.5m to Illinois expansion

October 6, 2026
Clinical trials supplies & documentation logistics, Logistics & Distribution, Manufacturing and Production, Warehousing & distribution API manufacture, Corporate, Pharmacy, investment, laboratory, pharma production

ESTEVE CDMO is investing a further $17.5m to expand capacity and containment capabilities at its Morton Grove facility in Illinois, …

AstraZeneca’s tozorakimab cuts COPD exacerbations by up to 34% in phase 3 trials

October 4, 2026
Asthma & COPD, COPD, asthma, clinical trials, monoclonal antibodies

AstraZeneca’s tozorakimab reduced moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease (COPD) in two phase 3 trials, cutting exacerbation …

Brenntag and dsm-firmenich expand biopharma vitamin partnership

October 4, 2026
Biopharmaceuticals, Pharmacy, cell culture, manufacturing

Brenntag Pharma and dsm-firmenich have entered a long-term global distribution partnership covering GMP-grade vitamins for biopharmaceutical manufacturing. Under the agreement, …

CeramTec expands German production capacity for orthopaedic ceramics

October 2, 2026
CeramTec, Germany, Marktredwitz, orthopaedic ceramics

CeramTec has opened a 12,000m² extension at its Marktredwitz site in Germany, adding around 5,000m² of production space for ceramic …

Migraine annual economic and quality-of-life burden in UK

October 1, 2026
AbbVie UK, Health Innovation Manchester, migraine, quality-of-life burden

Migraine affects an estimated 280,000 people across Greater Manchester and creates an annual economic and quality-of-life burden of around £870m, …

bit.bio expands human heart cell portfolio through myriamed partnership

September 30, 2026
Biotechnology, bit.bio, drug discovery, myriamed, safety testing

bit.bio has partnered with German biotechnology company myriamed to offer cryopreserved human induced pluripotent stem cell (iPSC)-derived cardiomyocytes for drug …

Phoenix Labs acquires Kent Pharma

September 29, 2026
Europe, Ireland, Kent Pharma, Phoenix Labs, acquisition

Phoenix Labs has acquired UK pharmaceutical distributor Kent Pharma from private equity firm Duke Street, expanding its presence in the …

Astoriom acquires Sampled’s UK stability storage operations

September 28, 2026
Astoriom, Roylance Scientific, Roylance Stability Storage, Sampled

Astoriom has acquired Roylance Stability Storage and Roylance Scientific, the Glasgow-based UK operations of life sciences stability storage provider Sampled. …

Alcami appoints Will Isom to lead laboratory services sales

September 28, 2026
Alcami

Alcami has appointed Will Isom as Vice President of Laboratory Services Sales, creating a new commercial role focused on its …

NIHR chief scientific adviser visits Huddersfield health innovation campus

September 25, 2026
Department of Health and Social Care, NHS, National Institute for Health and Care Research, University of Huddersfield

Professor Lucy Chappell, Chief Scientific Adviser to the Department of Health and Social Care and Chief Executive Officer of the …

One in three UK women with migraine say symptoms taken less seriously

September 24, 2026
Organon, The Migraine Trust, migraine, symptoms survey

One in three UK women who have experienced migraine say they believe their symptoms are taken less seriously because of …

The Gateway to Local Adoption Series

Latest content


Five Facts about COPD

October 11, 2026